Home Cart Sign in  
Chemical Structure| 4311-88-0 Chemical Structure| 4311-88-0

Structure of Necrostatin-1
CAS No.: 4311-88-0

Chemical Structure| 4311-88-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Necrostatin-1 is an inhibitor of RIP1 and can decrease TNF-α-induced necroptosis with EC50 of 490 nM.

Synonyms: Nec-1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Li, Xiao-huan ; Lv, Feng ; Li, Si-qi ; Deng, Hao-wei ; Tang, Li-ping ; Li, Ke-zhi , et al.

Abstract: Carnitine palmitoyltransferase 1A (CPT1A) has been implicated in the development of colorectal cancer (CRC), yet its role in ferroptosis remains to be fully understood. In this study, we found that CPT1A expression was associated with metastasis of CRC by gene datasets analysis and immunohistochemical staining of clinical samples, and it was upregulated in CRC cells compared with normal colon cell. The CCK-8, Transwell, and wound healing assays demonstrated that overexpression of CPT1A enhanced the viability, invasion, and migratory capacity of CRC cells. CPT1A expression was reduced following induction of ferroptosis in CRC cells, and this downregulation could be reversed by a ferroptosis inhibitor. Moreover, CPT1A overexpression inhibited ferroptosis in CRC cells. Nrf2, a well-known negative regulator of ferroptosis, was found to colocalize with CPT1A in CRC cells. Molecular docking, Co-IP assay and Ch-IP assay further confirmed an interaction between CPT1A and Nrf2. Notably, Nrf2 overexpression upregulated CPT1A expression, whereas Nrf2 knockdown produced the opposite effect. CPT1A overexpression led to activation of PI3K/AKT pathway in CRC cells. Inactivation of the PI3K/AKT pathway by the inhibitor partially reversed the anti-ferroptosis effect of CPT1A overexpression. Furthermore, inhibition of PI3K/AKT pathway suppressed Nrf2 expression, and reduce nuclear translocation of Nrf2, whereas activation of this pathway enhanced Nrf2 expression and nuclear translocation. In vivo experiments corroborated these findings, showing that CPT1A overexpression promoted Nrf2 expression, suppress ferroptosis, facilitated tumor growth, inactivated PI3K/AKT pathway. Taken together, our data suggest that CPT1A associates with metastasis of CRC, and inhibits ferroptosis through a regulatory feedback loop involving Nrf2 and PI3K/AKT pathway.

Keywords: Colorectal cancer ; CPT1A ; Ferroptosis ; Feedback loop

Purchased from AmBeed: ;

Alternative Products

Product Details of Necrostatin-1

CAS No. :4311-88-0
Formula : C13H13N3OS
M.W : 259.33
SMILES Code : CN1C(NC(CC2=CNC3=C2C=CC=C3)C1=O)=S
Synonyms :
Nec-1
MDL No. :MFCD00056916
InChI Key :TXUWMXQFNYDOEZ-UHFFFAOYSA-N
Pubchem ID :2828334

Safety of Necrostatin-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280

Related Pathways of Necrostatin-1

pyroptosis

Isoform Comparison

Biological Activity

Description
Necrostatin-1 (Nec-1) serves as a potent inhibitor of necroptosis, capable of crossing the blood-brain barrier, with an effective concentration (EC50) of 490 nM in Jurkat cells. It specifically inhibits RIP1 kinase activity (EC50=182 nM) and also functions as an inhibitor of IDO[1].
Target
  • TNF-α

    RIP1, EC50:490 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 10 μM 12 hours Evaluation of the role of Cys191 in GSDMD-NT pore formation Nat Immunol. 2020 Jul;21(7):736-745
BMDMs 50 µM 3 h Inhibition of necroptosis, reducing hypoxia-induced cell death J Exp Med. 2021 Sep 6;218(9):e20200667.
THP-1 cells 30 µM 1 hour To evaluate the inhibitory effect of Necrostatin-1 on necroptosis in THP-1 cells. The results showed that Necrostatin-1 completely inhibited HMGB1 release, supporting the major contribution of necrotic cell death in VEXAS. Nat Commun. 2024 Jan 30;15(1):910.
astrocytes 30 μM 4 h To evaluate the effect of RIPK1 kinase activity on inflammatory gene expression in astrocytes. Results showed that Nec-1s inhibited RIPK1 kinase activity and reduced inflammatory gene expression. Cell Rep. 2021 May 11;35(6):109112.
microglia 30 μM 2 h To evaluate the effect of RIPK1 kinase activity on inflammation and cell death in microglia. Results showed that Nec-1s inhibited RIPK1 kinase activity and reduced cell death. Cell Rep. 2021 May 11;35(6):109112.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Middle cerebral artery occlusion (MCAO) model Intracerebroventricular injection 20 mM Single injection, observed for 72 hours Nec-1 treatment significantly reduced ischemia-induced brain damage and neurological deficits, inhibited RIPK1 phosphorylation and its downstream signaling pathways. Aging Dis. 2019 Aug 1;10(4):807-817
Mice Experimental autoimmune encephalomyelitis (EAE) model Oral 30 mg/kg and 60 mg/kg Twice daily, continuous treatment To evaluate the therapeutic effect of RIPK1 kinase inhibitor in the EAE model. Results showed that RIPK1 kinase inhibitor significantly alleviated disease symptoms. Cell Rep. 2021 May 11;35(6):109112.
Mice Myocardial infarction model Subcutaneous injection 5 mg/kg Once daily, continued until the end of the experiment Inhibition of necroptosis, improving survival and cardiac function after myocardial infarction J Exp Med. 2021 Sep 6;218(9):e20200667.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.86mL

0.77mL

0.39mL

19.28mL

3.86mL

1.93mL

38.56mL

7.71mL

3.86mL

References

 

Historical Records

Categories